<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01624636</url>
  </required_header>
  <id_info>
    <org_study_id>CLFG316A2201</org_study_id>
    <nct_id>NCT01624636</nct_id>
  </id_info>
  <brief_title>Safety and Tolerability of Intravenous LFG316 in Wet Age-related Macular Degeneration (AMD).</brief_title>
  <official_title>A Multiple Dose, Two-cohort Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of Intravenous LFG316 in Patients With Neovascular Age-related Macular Degeneration</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      This study will assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and
      efficacy of successive intravenous (IV) doses of LFG316 in eligible patients with neovascular
      age-related macular degeneration (AMD)
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <start_date>December 2012</start_date>
  <completion_date type="Actual">May 2013</completion_date>
  <primary_completion_date type="Actual">May 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of anti-vascular endothelial growth factor (anti-VEGF) retreatment vs time</measure>
    <time_frame>Day 1 to Day 113 (starting from the day of dosing until the end of the study)</time_frame>
    <description>Number of retreatments with anti-VEGF treatments will be recorded.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number and percentage of patients with adverse events.</measure>
    <time_frame>Day 1 to Day 113 (starting from the day of dosing until the end of the study)</time_frame>
    <description>Adverse events will be determined based on descriptive analyses of vital signs, ECG evaluation, and clinical safety laboratory evaluations. All abnormalities will be flagged and summary statistics will be provided by treatment and visit/time.Will be tabulated by body system and preferred term with a breakdown by treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Effect of LFG316 on visual acuity</measure>
    <time_frame>Day 1 to Day 113</time_frame>
    <description>&quot;Early Treatment Diabetic Retinopathy Study&quot; (ETDRS best corrected visual acuity measured under ETDRS conditions). Number of letters correctly read will be recorded.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of LFG316 on central retinal thickness, choroidal neovascular membrane area and drusen volume.</measure>
    <time_frame>Day 1 to Day 113</time_frame>
    <description>summary statistics will be provided by treatment group, cohort and visit/time. Treatment effect will be assessed by comparison of mean change from baseline to Day 85 of patients who received or did not receive anti-VEGF therapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum concentrations of total LFG316 versus time</measure>
    <time_frame>Days 1, 8, 15, 22, 29, 43, 57, 78, 85 and 113 for both cohorts.</time_frame>
    <description>Blood samples will be collected.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum concentration of pharmacodynamic parameters (Weislab and C5) versus time</measure>
    <time_frame>screening and Days 1, 8, 15, 22, 29, 43, 57, 78, 85 and 113 (for both cohorts).</time_frame>
    <description>Blood samples will be collected.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">1</enrollment>
  <condition>Neovascular Age-related Macular Degeneration</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>LFG316: 10 mg/kg (2 doses in cohort 1)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>LFG316: 20 mg/kg (2 doses in cohort 1, 3 doses in cohort 2).</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LFG316</intervention_name>
    <arm_group_label>LFG316: 10 mg/kg (2 doses in cohort 1)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LFG316</intervention_name>
    <arm_group_label>LFG316: 20 mg/kg (2 doses in cohort 1, 3 doses in cohort 2).</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        - Active choroidal neovascular AMD in at least one eye.

        Exclusion Criteria:

          -  Retinal disease other than AMD that, in the investigator's opinion, would interfere
             with safety or study conduct.

          -  Choroidal neovascularization due to a cause other than AMD.

          -  In the study eye, media opacity that, in the investigator's opinion, would interfere
             with study conduct.

          -  Any disease or concomitant (or recent) medication expected to cause systemic
             immunosuppression.

          -  History of meningococcal meningitis in the past 10 years, or any history of recurrent
             meningitis.

          -  History of hospitalization for pneumococcal pneumonia within the past 3 years.

          -  History of serious systemic infection within the past 12 months.

          -  Any of the following treatments to the study eye within 7 days prior to study drug
             dosing: ranibizumab (Lucentis), bevacizumab (Avastin), pegaptanib (Macugen), or other
             VEGF inhibitor.

        Other protocol-defined inclusion/exclusion criteria may apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85014</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Winter Haven</city>
        <state>Florida</state>
        <zip>33880</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Beachwood/Cleveland</city>
        <state>Ohio</state>
        <zip>44122</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Austria</country>
    <country>Germany</country>
    <country>United Kingdom</country>
  </removed_countries>
  <verification_date>March 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 3, 2012</study_first_submitted>
  <study_first_submitted_qc>June 20, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 21, 2012</study_first_posted>
  <disposition_first_submitted>March 22, 2016</disposition_first_submitted>
  <disposition_first_submitted_qc>March 22, 2016</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">April 25, 2016</disposition_first_posted>
  <last_update_submitted>March 22, 2016</last_update_submitted>
  <last_update_submitted_qc>March 22, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 25, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>AMD</keyword>
  <keyword>Age-related Macular Degeneration</keyword>
  <keyword>Wet AMD</keyword>
  <keyword>Neovascular AMD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Degeneration</mesh_term>
    <mesh_term>Wet Macular Degeneration</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

